In the development of DNA vaccines and cell and gene therapies, manufacturing plasmid DNA creates a crucial bottleneck. Such a slowdown could intensify with the market for manufacturing DNA plasmids ...

DUBLIN--(BUSINESS WIRE)--The "Viral Vectors & Plasmid DNA Manufacturing Market Report 2024-2034" report has been added to ResearchAndMarkets.com's offering. Overall world revenue for the viral vectors ...

Even as mRNA specialist BioNTech plants its manufacturing flag on continents around the globe, the company is still advancing production capabilities at home. Thursday, BioNTech said it finished ...

New York, USA, May 04, 2026 (GLOBE NEWSWIRE)-- Global Plasmid DNA Manufacturing Market Anticipates Impressive Growth Trajectory at a CAGR of ~18% by 2034 | DelveInsight The plasmid DNA manufacturing ...

In 2025, North America led the viral vectors and plasmid DNA manufacturing market, contributing 49% of the total revenue. Among vector types, the AAV segment emerged as a key growth driver, accounting ...

Wacker and Gearbox Biosciences agreed to collaborate to advance plasmid DNA manufacturing technologies. By combining Wacker’s expertise in GMP manufacturing of biologics, including pDNA, with Gearbox ...

Plasmid DNA (pDNA) constructs are used for a number of key applications, including gene therapy and mRNA. Manufacturing plasmids is therefore a crucial part of biotechnology. A good manufacturing ...

WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL), today announced a High Quality (HQ) plasmid manufacturing collaboration with Fondazione Telethon. The ...

Dublin, April 20, 2026 (GLOBE NEWSWIRE)-- The "Viral Vector and Plasmid DNA Manufacturing Market (7th Edition): Industry Trends and Global Forecasts, till 2035" report has been added to ...

An operator trained in GMP conditions is checking centrifugation parameters on the touchscreen of the device Attractive cost of goods gives plasmid DNA commercial path forward and positions Kaneka ...

MAINZ, Germany, February 2, 2023 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced construction completion of the Company’s first proprietary plasmid DNA manufacturing facility ...